Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2012

View Archived Issues

Radius Health scientists design novel SARMs

Roche presents new potential products to treat/prevent CMV infection

Biota Holdings presents novel antibacterials

Interferon-free combination therapy shows promise to treat chronic hepatitis C

Encouraging phase I data reported on candidate arthritis immunotherapy

Pretargeted radioimmunotherapy is safe, specific and fast in patients with colorectal tumors

Korean team discovers novel serum biomarker of ovarian carcinoma

Genocea Biosciences presents potential HSV-2 vaccine at ongoing conference

Proteostasis Therapeutics to collaborate with CFFT

Interim data reported from combination study in CF

Sunovion confirms upcoming availability of ciclesonide nasal aerosol

Iluvien gains U.K. marketing authorization

Aeterna Zentaris regains rights to perifosine

Galleon Pharmaceuticals reports phase I GAL-021 study results

FDA clears p53 image analysis algorithm

Alder BioPharmaceuticals launches phase I trial of mAb for migraine

German BfArM issues recommendation on Pliaglis MAA

Santen and Bayer Yakuhin enter copromotion agreement

First-in-human data disclosed on topical RNAi drug for ocular pain

New phase III study of Adcetris begins

Immunomic Therapeutics clear to launch phase I trial of Japanese red cedar allergy vaccine

New candidate drugs for tuberculosis designed at GSK

Investigation at Roche yields novel TWEAK-specific antibodies

Envoy Therapeutics receives second grant from Michael J. Fox Foundation

FDA extends PDUFA date for Marqibo NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...